Leaders of India’s $15 billion pharmaceuticals industry, a major supplier of affordable generics to the world, have joined public health activists against the US led Trans-Pacific Partnership trade deal.
SNSK (Shiv Nadar – Sanjay Kalra) Associates are establishing a $500 million proprietary fund to acquire US healthcare technology companies and platforms that can bring greater efficiencies to the US healthcare system.
The trio – US Ambassador to India, Richard Verma; legendary actor, Amitabh Bachchan and Chairman of Sir Ratan Tata Trust, Ratan Tata – recently launched the ‘Mumbai Dialogue – Towards a TB-Free India’.
Indian pharmaceutical firm Cipla has agreed to buy two generics businesses in the United States, InvaGen Pharmaceuticals Inc and Exelan Pharmaceuticals Inc in an all-cash deals worth $550 million, as part of an effort to boost its presence in the world’s largest generics market.
Ambassador Richard Verma has said that Indo-US relations have reached new level and that US has found a good partner in Prime Minister Modi.